{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:47:20Z","timestamp":1788202040973,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116120","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:41:58Z","timestamp":1764348118000},"page":"116120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Waldenstr\u00f6m\u2019s macroglobulinemia: The LYSA pragmatic guidelines"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-755X","authenticated-orcid":false,"given":"Damien","family":"Roos-Weil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tomowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Nguyen-Khac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-9536","authenticated-orcid":false,"given":"Florian","family":"Bouclet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Aurran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-0089","authenticated-orcid":false,"given":"Eric","family":"Durot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ghez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Hivert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali Le Garff","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lepretre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3854-4209","authenticated-orcid":false,"given":"Lydia","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Moslemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0451-2471","authenticated-orcid":false,"given":"Laurence","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116120_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2025.116120_bib2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom\u2019s macroglobulinemia on diagnostic and response criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/leu.2013.124","article-title":"Multiparameter flow cytometry for the identification of the Waldenstr\u00f6m\u2019s clone in IgM-MGUS and Waldenstr\u00f6m\u2019s Macroglobulinemia: new criteria for differential diagnosis and risk stratification","volume":"28","author":"Paiva","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2025.116120_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.15584","article-title":"CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation","volume":"184","author":"Raimbault","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib7","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3324\/haematol.2019.227272","article-title":"MYD88 in the driver\u2019s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications","volume":"104","author":"de Groen","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ajh.26339","article-title":"Cytogenetic and molecular abnormalities in Waldenstr\u00f6m\u2019s macroglobulinemia patients: correlations and prognostic impact","volume":"96","author":"Krzisch","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib9","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib10","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41598-017-01998-5","article-title":"Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2025.116120_bib11","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large b-cell lymphoma: analysis of 361 Cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.116120_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib13","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic Landscape of CXCR4 Mutations in Waldenstr\u00f6m Macroglobulinemia","volume":"22","author":"Poulain","year":"2016","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.116120_bib15","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474086.2019.1649132","article-title":"CXCR4 mutations affect presentation and outcomes in patients with Waldenstr\u00f6m macroglobulinemia: a systematic review","volume":"12","author":"Castillo","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib17","first-page":"1","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","author":"Castillo","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2025.116120_bib18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/2159-8290.CD-18-0873","article-title":"A recurrent activating missense mutation in waldenstr\u00f6m macroglobulinemia affects the DNA binding of the ETS Transcription Factor SPI1 and enhances proliferation","volume":"9","author":"Roos-Weil","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.116120_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116120_bib20","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 Mutation and Its Prognostic Significance in Waldenstrom\u2019s Macroglobulinemia","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116120_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr\u00f6m macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib22","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","article-title":"Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr\u00f6m macroglobulinemia","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2025.116120_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2023.03.007","article-title":"Report of Consensus Panel 3 from the 11th International workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia: recommendations for molecular diagnosis in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"60","author":"Garcia-Sanz","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib24","doi-asserted-by":"crossref","first-page":"E148","DOI":"10.1002\/ajh.25802","article-title":"Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations","volume":"95","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib25","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1002\/ajh.26184","article-title":"Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenstr\u00f6m macroglobulinemia","volume":"96","author":"Demos","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-0716-2950-5_5","article-title":"MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring: ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation","volume":"2621","author":"Drandi","year":"2023","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"10.1016\/j.ejca.2025.116120_bib27","article-title":"Cytogenetics in the management of mature B-cell non-Hodgkin lymphomas: guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique Hematologique (GFCH)","volume":"71","author":"Lefebvre","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.ejca.2025.116120_bib28","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","article-title":"Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom\u2019s macroglobulinemia","volume":"69","author":"Braggio","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.116120_bib29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib30","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ajh.26339","article-title":"Cytogenetic and molecular abnormalities in Waldenstr\u00f6m\u2019s macroglobulinemia patients: correlations and prognostic impact","volume":"96","author":"Krzisch","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjh.17028","article-title":"6q deletion in Waldenstr\u00f6m macroglobulinaemia negatively affects time to transformation and survival","volume":"192","author":"Garc\u00eda-Sanz","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib32","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.leu.2404314","article-title":"Trisomy 4, a new chromosomal abnormality in Waldenstr\u00f6m\u2019s macroglobulinemia: a study of 39 cases","volume":"20","author":"Terr\u00e9","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2025.116120_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstr\u00f6m Macroglobulinaemia: a task force from the 8th international workshop on waldenstr\u00f6m macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3324\/haematol.12107","article-title":"Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom\u2019s macroglobulinemia","volume":"93","author":"Itzykson","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib35","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1158\/1078-0432.CCR-10-2954","article-title":"The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia","volume":"17","author":"Leleu","year":"2011","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.116120_bib36","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression risk stratification of asymptomatic waldenstr\u00f6m macroglobulinemia","volume":"37","author":"Bustoros","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib37","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstrom macroglobulinemia: long-term results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib39","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib40","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2025.116120_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102060","article-title":"Trends in risk for therapy-related myelodysplastic syndrome\/acute myeloid leukemia after initial chemo\/immunotherapy for common and rare lymphoid neoplasms, 2000-2018","volume":"61","author":"Morton","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejca.2025.116120_bib42","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2025.116120_bib43","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/ajh.26895","article-title":"Bendamustine plus rituximab for the treatment of Waldenstr\u00f6m Macroglobulinemia: patient outcomes and impact of bendamustine dosing","volume":"98","author":"Arulogun","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.27524","article-title":"First-line treatment of Waldenstr\u00f6m\u2019s macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies","volume":"100","author":"Autore","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib45","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2025.116120_bib46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.15718","article-title":"Bendamustine plus rituximab in newly-diagnosed Waldenstr\u00f6m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)","volume":"186","author":"Laribi","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib47","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ajh.26210","article-title":"Assessment of fixed-duration therapies for treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia","volume":"96","author":"Abeykoon","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ejca.2025.116120_bib48","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1111\/bjh.19409","article-title":"Long-term results of Waldenstr\u00f6m macroglobulinaemia treatment by bendamustine and rituximab: a study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"204","author":"Laribi","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib49","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib50","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib51","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenstr\u00f6m\u2019s Macroglobulinemia: a prospectively randomized trial of the european consortium for waldenstr\u00f6m\u2019s macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib52","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172996","article-title":"Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis","volume":"12","author":"Sidana","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2025.116120_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstr\u00f6m\u2019s Macroglobulinemia: final analysis from the randomized phase III iNNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib56","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: final analysis From the Randomized Phase III ASPEN Study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib57","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24955","article-title":"MYD88 mutation status does not impact overall survival in Waldenstr\u00f6m macroglobulinemia","volume":"93","author":"Abeykoon","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib59","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2025.116120_bib60","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstr\u00f6m\u2019s macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr\u00f6m macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib62","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib63","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.18055","article-title":"Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstr\u00f6m macroglobulinaemia: a french Innovative Leukaemia Organization study","volume":"197","author":"Tomowiak","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib65","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000473","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia: recommendations of the French CLL Study Group (FILO)","volume":"4","author":"Quinquenel","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.ejca.2025.116120_bib66","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3324\/haematol.2022.281053","article-title":"Inflammation in Waldenstr\u00f6m macroglobulinemia is associated with 6q deletion and need for treatment initiation","volume":"107","author":"Forgeard","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib67","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib68","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: Etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib69","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2014-03-565135","article-title":"Treatment recommendations for patients with Waldenstr\u00f6m macroglobulinemia (WM) and related disorders: IWWM-7 consensus","volume":"124","author":"Dimopoulos","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib70","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib71","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/ajh.26895","article-title":"Bendamustine plus rituximab for the treatment of Waldenstr\u00f6m Macroglobulinemia: patient outcomes and impact of bendamustine dosing","volume":"98","author":"Arulogun","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.14826","article-title":"Dexamethasone, rituximab and cyclophosphamide for relapsed and\/or refractory and treatment-na\u00efve patients with Waldenstrom macroglobulinemia","volume":"179","author":"Paludo","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib73","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib74","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ajh.24405","article-title":"Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom\u2019s macroglobulinemia","volume":"91","author":"Souchet","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib75","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.26303","article-title":"Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia","volume":"118","author":"Tedeschi","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.116120_bib76","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","article-title":"Bortezomib is active in patients with untreated or relapsed Waldenstrom\u2019s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib77","first-page":"1655","article-title":"Treatment of relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia with bortezomib","volume":"90","author":"Dimopoulos","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib78","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1080\/10428194.2017.1307357","article-title":"A phase II Bayesian sequential clinical trial in advanced Waldenstr\u00f6m macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone","volume":"58","author":"Leblond","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2025.116120_bib79","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","article-title":"Multicenter Clinical Trial of Bortezomib in Relapsed\/Refractory Waldenstrom\u2019s Macroglobulinemia: results of WMCTG Trial 03-248","volume":"13","author":"Treon","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2025.116120_bib80","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.21.00105","article-title":"Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstr\u00f6m\u2019s Macroglobulinemia: final analysis of the Phase I\/II HOVON124\/ECWM-R2 Study","volume":"40","author":"Kersten","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib82","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116120_bib83","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of ibrutinib monotherapy in symptomatic, previously treated patients with waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos MA","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib85","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-21-1497","article-title":"Single-Agent Ibrutinib for Rituximab-Refractory Waldenstr\u00f6m Macroglobulinemia: final analysis of the substudy of the phase III InnovateTM Trial","volume":"27","author":"Trotman","year":"2021","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.116120_bib86","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2025.116120_bib87","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/01.HS9.0000847388.33116.c7","article-title":"P1130: Acalabrutinib in treatment-naive or relapsed\/refractory waldenstr\u00f6m macroglobulinemia: 5-year follow-up of a phase 2, single-arm study","volume":"6","author":"Owen","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.ejca.2025.116120_bib88","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/cas.15344","article-title":"Two-year outcomes of tirabrutinib monotherapy in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"113","author":"Sekiguchi","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2025.116120_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejca.2025.116120_bib90","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib91","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024667","article-title":"Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R\/R CLL\/SLL: final comparative analysis of ALPINE","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib92","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116120_bib93","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2022-159123","article-title":"Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed \/ Refractory Waldenstr\u00f6m Macroglobulinemia: results from the phase 1\/2 BRUIN Study","volume":"140","author":"Palomba","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib94","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2024-199212","article-title":"Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenstr\u00f6m Macroglobulinemia: results from the Phase 1 CaDAnCe-101 Study","volume":"144","author":"Seymour","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib95","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton\u2019s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib96","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated waldenstr\u00f6m macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116120_bib97","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2022-155610","article-title":"Ibrutinib and Venetoclax in Previously Untreated Waldenstr\u00f6m Macroglobulinemia","volume":"140","author":"Castillo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib98","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","article-title":"Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia","volume":"5","author":"Tomowiak","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2025.116120_bib99","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-06076-1","article-title":"Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed\/ refractory patients with Waldenstr\u00f6m\u2019s macroglobulinemia","author":"Tomowiak","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2025.116120_bib100","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood.2024024452","article-title":"High efficacy of CD19 CAR T cells in patients with transformed Waldenstr\u00f6m macroglobulinemia","volume":"143","author":"Durot","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116120_bib101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbmt.2016.10.010","article-title":"Allogeneic Transplantation for Relapsed Waldenstr\u00f6m Macroglobulinemia and Lymphoplasmacytic Lymphoma","volume":"23","author":"Cornell","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.ejca.2025.116120_bib102","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3324\/haematol.2009.017814","article-title":"Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstr\u00f6m\u2019s macroglobulinemia. Results of a retrospective analysis of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"95","author":"Garnier","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib103","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1016\/j.clml.2020.05.021","article-title":"Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenstr\u00f6m Macroglobulinemia: a systematic review and meta-analysis","volume":"20","author":"Parrondo","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2025.116120_bib104","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.184176","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: evidence for a graft-versus-lymphoma effect","author":"Maffini","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2025.116120_bib105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.seminhematol.2025.04.003","article-title":"Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom\u2019s Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom\u2019s Macroglobulinemia","volume":"62","author":"Durot","year":"2025","journal-title":"Semin Hematol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:41:13Z","timestamp":1768844473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":105,"alternative-id":["S0959804925010068"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116120","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Waldenstr\u00f6m\u2019s macroglobulinemia: The LYSA pragmatic guidelines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116120"}}